Spotlight
Video

Can a "heat shock protein inhibitor" in standard chemo improve outcomes in advanced NSCLC?

cancergrace has 804 videos Subscribe Here

Loading........
Description: http://cancerGRACE.org/...

Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.

GRACEcastUC 134 Lung
Shared By : cancergrace
Posted on : 06/19/13
Added : 4 years ago
Category : General